Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$104.83 USD

104.83
4,831,663

-1.96 (-1.84%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $104.84 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market

by Zacks Equity Research

TMO tops Q2 estimates as new product launches and solid segment growth fuel revenue gains despite margin pressure.

Zacks Equity Research

Boston Scientific (BSX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

ISRG Stock Gains on Q2 Earnings & Sales Beat, Gross Margin Contracts

by Zacks Equity Research

Intuitive Surgical's second-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.

Zacks Equity Research

Boston Scientific (BSX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of +4.17% and +3.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Molina to Report Q2 Earnings: Healthy Revenues, Weak Pulse on Earnings

by Zacks Equity Research

MOH's Q2 revenues are set to rise nearly 10%, but rising costs cloud its profit outlook.

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY rides strong global demand and CyberKnife momentum, but order declines and backlog pressure temper the outlook.

Zacks Equity Research

Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Zacks Equity Research

Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat

by Zacks Equity Research

ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.

Zacks Equity Research

ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal

by Zacks Equity Research

Zimmer Biomet eyes long-term gains with the $177M Monogram buyout, aiming to expand its robotic knee surgery offerings by 2027.

Zacks Equity Research

ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines

by Zacks Equity Research

AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss outlook.

Zacks Equity Research

Reasons to Add DENTSPLY SIRONA Stock to Your Portfolio Now

by Zacks Equity Research

XRAY gains traction with digital implants, R&D strength, and Q1 margin growth despite softness in Europe.

Zacks Equity Research

PAHC or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

GMED Unveils Next-Gen Oscillating System DuraPro: Stock to Gain?

by Zacks Equity Research

Globus Medical debuts DuraPro with Excelsius integration, boosting its Power Portfolio.

Zacks Equity Research

Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings?

by Zacks Equity Research

BSX eyes strong Q2 with MedSurg momentum, solid Cardiovascular growth and benefits from key tech acquisitions.

Zacks Equity Research

Why Boston Scientific (BSX) Outpaced the Stock Market Today

by Zacks Equity Research

Boston Scientific (BSX) reached $104.33 at the closing of the latest trading day, reflecting a +1.09% change compared to its last close.

Zacks Equity Research

Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?

by Zacks Equity Research

ELV's second-quarter earnings may face pressure as rising costs and lower Medicaid memberships offset strong revenue gains.

Zacks Equity Research

Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms

by Zacks Equity Research

BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings.

Zacks Equity Research

Boston Scientific (BSX) Crossed Above the 20-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Zacks Equity Research

Here's How Much a $1000 Investment in Boston Scientific Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Sridatri Sarkar headshot

3 AI-Driven Medical Device Stocks to Watch in 2025

by Sridatri Sarkar

BSX, JNJ and GEHC are leveraging AI to boost device performance, diagnostics and surgical precision in 2025.

Zacks Equity Research

Is Concentra Group Holdings Parent, Inc. (CON) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Concentra Group (CON) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Zacks Equity Research

Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?

by Zacks Equity Research

Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.